GlassScriptPhysician profile
Douglas M David
NPI 1396733101
$8,169.94
in general payments reported to CMS, 2019-2025
44 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $325 · 2021: $1,445 · 2022: $1,355 · 2023: $1,869 · 2024: $998 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.51 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,051.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $797.62 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $768.52 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $758.13 | 2019-2025 | |
| Amgen INC. | $623.42 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $516.57 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $399.25 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $392.50 | 2019-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $297.84 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.67 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $241.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.13 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $166.66 | 2021 | |
| Sumitomo Pharma America, INC. | $135.74 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $121.99 | 2023-2025 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.